Drug Profile
Research programme: spinal muscular atrophy therapies - Spotlight Innovation
Alternative Names: STL-182Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Indiana University School of Medicine; The Laboratory for Drug Discovery in Neurodegeneration
- Developer Indiana University School of Medicine
- Class Small molecules
- Mechanism of Action SMN complex protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Spinal muscular atrophy
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Spinal muscular atrophy in USA (PO) (Spotlight Innovation pipeline, September 2023)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA (PO)
- 16 Aug 2017 Spotlight Innovation entered into a research agreement with Indiana University to develop spinal muscular atrophy therapies